CJC 1295 NO DAC 5 mg +IPAMORELIN 5 mg Research Profile

Current catalog abstract

Documented material overview

CJC-1295 without DAC combined with Ipamorelin is a dual-peptide formulation designed to synergistically stimulate endogenous growth hormone (GH) secretion through complementary mechanisms. CJC-1295 no DAC is a modified analog of growth hormone-releasing hormone (GHRH) that binds to GHRH receptors in the anterior pituitary, promoting pulsatile GH release in a manner that closely mimics physiological patterns. Ipamorelin, a selective growth hormone secretagogue, acts on ghrelin (GHS-R1a) receptors to further enhance GH secretion without significantly influencing cortisol or prolactin levels. When used together in research settings, these peptides produce a coordinated effect that amplifies GH pulses while maintaining a short-acting profile due to the absence of DAC, allowing for greater control over timing and frequency of stimulation. This combination has been studied for its effects on endocrine signaling, metabolic regulation, and tissue repair processes, as well as its ability to model natural growth hormone dynamics. Both peptides are structurally engineered for improved stability relative to endogenous hormones while retaining rapid clearance characteristics. This product is intended strictly for research purposes only and is not for human consumption, clinical use, or therapeutic application.